Back to News
Market Impact: 0.3
Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Scholar Rock resubmitted its Marketing Authorization Application to the European Medicines Agency, seeking approval of apitegromab to treat children and adults with spinal muscular atrophy. The article excerpt provides no additional details on the application or a regulatory decision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
SRRK0.45
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Why is T-Mobile stock tumbling today?